23 active not recruiting. 23 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 23 | Active not recruiting 23 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dymista in Chinese Adolescents Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate - Allergic Rhinitis Due to Allergens | Phase 4 | Active not recruiting | Viatris Inc. | 100 | 2026-05-08 | 2026-09-29 |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis lebrikizumab - Atopic Dermatitis | Phase 4 | Active not recruiting | Johann E Gudjonsson MD PhD | 48 | 2025-07-02 | 2026-09-15 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma dupilumab, Matching Placebo, ICS/LABA - Asthma | Phase 4 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-08-26 | 2026-05-22 |
| FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA Omalizumab - Food Allergy | Phase 4 | Active not recruiting | AAADRS Clinical Research Center | 20 | 2024-06-03 | 2025-08-14 |
| Dupilumab for Eosinophilic Esophagitis With Severe Strictures Dupilumab - Eosinophilic Esophagitis, EoE | Phase 4 | Active not recruiting | University of North Carolina, Chapel Hill | 23 | 2024-05-16 | 2026-04-29 |
| Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care Albuterol and budesonide inhalation aerosol - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 1511 | 2024-05-10 | 2026-07-16 |
| Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 1358 | 2024-04-16 | 2026-10-06 |
| The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System - Asthma, COPD | Phase 4 | Active not recruiting | University of California, San Francisco | 40 | 2024-04-09 | 2026-08-13 |
| REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study Mepolizumab, Spirometry - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 336 | 2024-03-20 | 2025-08-01 |
| A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis dupilumab - Dermatitis Atopic | Phase 4 | Active not recruiting | Sanofi | 48 | 2024-02-22 | 2026-04-13 |
| A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) Dupilumab, Placebo - Eosinophilic Oesophagitis | Phase 4 | Active not recruiting | Sanofi | 69 | 2023-11-29 | 2026-09-30 |
| Bodewell Products for the Treatment of Atopic Dermatitis Bodewell Calming Cream - Atopic Dermatitis | Phase 4 | Active not recruiting | University of Alabama at Birmingham | 15 | 2023-11-01 | 2026-03-02 |
| Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks Mepolizumab Injection, Functional Endoscopic Sinus Surgery (FESS). - Chronic Rhinosinusitis with Nasal Polyps, Asthma | Phase 4 | Active not recruiting | Vibeke Backer | 58 | 2023-04-01 | 2025-03-30 |
| Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month - Asthma | Phase 4 | Active not recruiting | Hospices Civils de Lyon | 20 | 2023-03-09 | 2024-11-18 |
| INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION Fluticasone propionate nasal spray, Fluticasone propionate-azelastine nasal spray - Allergic Rhinitis | Phase 4 | Active not recruiting | Pamukkale University | 61 | 2022-12-01 | 2026-02-17 |
| An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis Mycophenolate Mofetil plus prednisolone, Prednisolone - Hypersensitivity Pneumonitis | Phase 4 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 144 | 2022-11-23 | 2026-06-03 |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Sanofi | 1339 | 2021-12-16 | 2026-04-16 |
| Investigating Dupilumab's Effect in Asthma by Genotype Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Boston Children's Hospital | 150 | 2021-09-08 | 2026-02-23 |
| Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease Montelukast, Placebo - Meniere Disease, Allergic Rhinitis | Phase 4 | Active not recruiting | House Ear Institute | 39 | 2021-06-07 | 2025-03-18 |
| Epigenetic Health Benefits of Budesonide Budesonide Nasal, Placebo - Epigenetic Effects of Intranasal Steroids, Environmental Exposure | Phase 4 | Active not recruiting | University of British Columbia | 20 | 2021-01-07 | 2025-03-27 |
Showing 20 of 23. Sign in to see all of them.
Asthma (10) · Rhinitis, Allergic (4) · Dermatitis, Atopic (3) · Eosinophilic Esophagitis (2) · Food Hypersensitivity (2) · Alveolitis, Extrinsic Allergic (1) · Constriction, Pathologic (1) · Dermatitis, Allergic Contact (1) · Eczema (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Meniere Disease (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Eosinophilia (1) · Vertigo (1)
Immune System Diseases (23) · Hypersensitivity, Immediate (22) · Respiratory Hypersensitivity (15) · Respiratory Tract Diseases (15) · Bronchial Diseases (10) · Lung Diseases (10) · Lung Diseases, Obstructive (10) · Dermatitis (5) · Skin Diseases (5) · Skin Diseases, Eczematous (5) · Skin and Connective Tissue Diseases (5) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Rhinitis (4)
dupilumab (7) · mepolizumab (3) · Fluticasone (2) · Acetylcysteine (1) · Albuterol (1) · Budesonide (1) · Cholecalciferol (1) · Methods (1) · Mycophenolic Acid (1) · N-monoacetylcystine (1) · Omalizumab (1) · Prednisolone (1) · Propionates (1) · Therapeutics (1) · Vitamin D (1)
Sanofi (3) · AstraZeneca (2) · GlaxoSmithKline (2) · AAADRS Clinical Research Center (1) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1) · Hospices Civils de Lyon (1) · House Ear Institute (1) · Johann E Gudjonsson MD PhD (1) · Murdoch Childrens Research Institute (1) · Pamukkale University (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Regeneron Pharmaceuticals (1) · University of Alabama at Birmingham (1) · University of British Columbia (1)
United States (16) · Canada (7) · China (3) · Denmark (3) · Germany (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Brazil (2) · France (2) · India (2) · Japan (2) · Poland (2) · Puerto Rico (2) · South Korea (2)
Christopher Carlsten, MD (1) · Duc Tung Nguyen, Dr. (1) · Evan S Dellon, MD, MPH (1) · Gilles Devouassoux, Pr (1) · Johann E. Gudjonsson, MD, PhD (1) · John Fahy, MD, MS (1) · Kirsten Perrett, MD PhD (1) · Mario Castro, MD (1) · Mary J Derebery, MD (1) · Sahajal Dhooria, MD, DM (1) · Tiffany Mayo, MD (1) · Vibeke B Backer, Professor (1)
PMID 36891077, PMID 37946302, PMID 41084592, PMID 41759721, PMID 42474701, PMID 42742633, PMID 42861971
2018 (1), 2023 (1), R01HL080414 (1), U01AI143514 (1)